These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21367672)

  • 1. Late regression of Cypher in-stent restenosis.
    Yamaguchi H; Takaoka J; Miyamura A; Atsuchi N; Atsuchi Y; Kaneda H
    Cardiovasc Revasc Med; 2011; 12(5):341-2. PubMed ID: 21367672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
    JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological finding of sirolimus-eluting stent (SES) restenosis lesion with black hole appearance on intravascular ultrasound.
    Goto K; Shiode N; Shirota K; Fukuda Y; Kitamura F; Tominaga K; Kato Y; Miura H; Inoue K; Nobuyoshi M
    Circ J; 2009 Oct; 73(10):1969-71. PubMed ID: 19179779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents.
    Kufner S; Massberg S; Dommasch M; Byrne RA; Tiroch K; Ranftl S; Fusaro M; Schömig A; Kastrati A; Mehilli J;
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):161-6. PubMed ID: 21400652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. My stent is better than your stent...Or is it?
    Bates ER; Menees DS
    JACC Cardiovasc Interv; 2011 May; 4(5):551-3. PubMed ID: 21596328
    [No Abstract]   [Full Text] [Related]  

  • 7. Nevo stent: a successful stent makeover.
    Belardi JA
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):52-3. PubMed ID: 21181969
    [No Abstract]   [Full Text] [Related]  

  • 8. Serial angiographic and intravascular ultrasound evaluation to interrogate the presence of late "catch-up" phenomenon after Cypher® sirolimus-eluting stent implantation.
    Chamié D; Abizaid A; Costa JR; Feres F; Almiro da Silva JF; Mattos LA; Staico R; Costa RA; Abizaid A; Tanajura LF; Sousa AG; Sousa JE
    Int J Cardiovasc Imaging; 2011 Jul; 27(6):867-74. PubMed ID: 21082255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiographic and intravascular ultrasound follow up of paclitaxel- and sirolimus-eluting stent after poststent high-pressure balloon dilation: from the poststent optimal stent expansion trial.
    Park SM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y; Kang WC; Ahn T; Kim BK; Oh SJ; Jeon DW; Yang JY
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):15-21. PubMed ID: 20928842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical and angiographic outcomes after implantation of sirolimus-eluting stents with a "modified mini-crush" technique in coronary bifurcation lesions.
    Yang HM; Tahk SJ; Woo SI; Lim HS; Choi BJ; Choi SY; Yoon MH; Park JS; Zheng M; Hwang GS; Kang SJ; Shin JH
    Catheter Cardiovasc Interv; 2009 Jul; 74(1):76-84. PubMed ID: 19360861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of bifurcation lesions treated with novel drug-eluting dedicated bifurcation stent system: intravascular ultrasound results of the AXXESS PLUS trial.
    Miyazawa A; Ako J; Hassan A; Hasegawa T; Abizaid A; Verheye S; McClean D; Neumann FJ; Grube E; Honda Y; Fitzgerald PJ
    Catheter Cardiovasc Interv; 2007 Dec; 70(7):952-7. PubMed ID: 18044777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of reduced-dose sirolimus-eluting stents in the human coronary artery: serial IVUS analysis of neointimal hyperplasia and luminal dimension.
    Nakamura M; Abizaid A; Hirohata A; Honda Y; Sousa JE; Fitzgerald PJ
    Catheter Cardiovasc Interv; 2007 Dec; 70(7):946-51. PubMed ID: 17621671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravascular ultrasound analysis of small vessel lesions treated with the Sparrow coronary stent system: results of the CARE II trial.
    Kume T; Waseda K; Koo BK; Yock PG; Botelho R; Verheye S; Whitbourn R; Meredith I; Worthley S; Hai KT; Honda Y; Abizaid A; Fitzgerald PJ
    Catheter Cardiovasc Interv; 2014 Jan; 83(1):19-24. PubMed ID: 23413202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NEVO™: a new generation of sirolimus-eluting coronary stent.
    Falotico R; Parker T; Grishaber R; Price S; Cohen SA; Rogers C
    EuroIntervention; 2009 Dec; 5 Suppl F():F88-93. PubMed ID: 22100684
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute and long-term outcomes of ostial stentings among bare-metal stents, sirolimus-eluting stents, and paclitaxel-eluting stents.
    Hsieh IC; Hsieh MJ; Chang SH; Wang CY; Lee CH; Lin FC; Chen CC
    Coron Artery Dis; 2013 May; 24(3):224-30. PubMed ID: 23571311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low coronary flow velocity and shear stress predict restenosis after sirolimus-eluting stent implantation.
    Hikita H; Sato A; Nozato T; Kawashima T; Takahashi Y; Kuwahara T; Takahashi A
    Scand Cardiovasc J; 2009; 43(5):298-303. PubMed ID: 19263268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crush stenting with paclitaxel-eluting or sirolimus-eluting stents for the treatment of coronary bifurcation lesions.
    Chen S; Zhang J; Ye F; Zhu Z; Lin S; Tian N; Liu Z; Fang W; Chen Y; Sun X; Kwan TW
    Angiology; 2008; 59(4):475-83. PubMed ID: 18388098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of diabetes mellitus on vessel response in the drug-eluting stent era: pooled volumetric intravascular ultrasound analyses.
    Sakata K; Waseda K; Kume T; Otake H; Nakatani D; Yock PG; Fitzgerald PJ; Honda Y
    Circ Cardiovasc Interv; 2012 Dec; 5(6):763-71. PubMed ID: 23149332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing?
    Finn AV; Nakazawa G; Kolodgie FD; Virmani R
    JACC Cardiovasc Interv; 2009 Apr; 2(4):300-2. PubMed ID: 19463440
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.